Dr. Hoimes is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
20 Duke Medicine Cir
Durham, NC 27710
Education & Training
Yale School of MedicinePost-Doctoral Fellowship, 2008 - 2012
Yale-New Haven HospitalFellowship, Genitourinary Oncology, 2009 - 2010- Yale-New Haven Medical CenterFellowship, Hematology and Medical Oncology, 2006 - 2009
Penn State Milton S Hershey Medical CenterChief Residency, Internal Medicine, 2005 - 2006- Penn State Milton S Hershey Medical CenterResidency, Internal Medicine, 2002 - 2005
NYIT College Of Osteopathic MedicineClass of 2001
Certifications & Licensure
OH State License 2013 - 2026
NC State License 2020 - 2025
CT State License 2009 - 2013
PA State License 2002 - 2012
Clinical Trials
- Phase 2 Study of Docetaxel +/- OGX-427 in Patients With Relapsed or Refractory Metastatic Bladder Cancer Start of enrollment: 2013 Apr 01
- Neoadjuvant Pembrolizumab in Combination With Gemcitabine Therapy in Cis-eligible/Ineligible UC Subjects Start of enrollment: 2015 May 27
Publications & Presentations
PubMed
- 102 citationsEnfortumab Vedotin Plus Pembrolizumab in Previously Untreated Advanced Urothelial Cancer.Christopher J Hoimes, Thomas W Flaig, Matthew I Milowsky, Terence W Friedlander, Mehmet Asim Bilen
Journal of Clinical Oncology. 2023-01-01 - 49 citationsEnfortumab Vedotin With or Without Pembrolizumab in Cisplatin-Ineligible Patients With Previously Untreated Locally Advanced or Metastatic Urothelial Cancer.Peter H O'Donnell, Matthew I Milowsky, Daniel P Petrylak, Christopher J Hoimes, Thomas W Flaig
Journal of Clinical Oncology. 2023-09-01 - 26 citationsRandomized Phase III Trial of Gemcitabine and Cisplatin With Bevacizumab or Placebo in Patients With Advanced Urothelial Carcinoma: Results of CALGB 90601 (Alliance)Jonathan E. Rosenberg, Karla A Ballman, Susan Halabi, Pamela J. Atherton, Amir Mortazavi
Journal of Clinical Oncology. 2021-05-14
Books/Book Chapters
Press Mentions
Seattle Genetics and Astellas Announce Results from Phase 1 Trial of Investigational Agent Enfortumab Vedotin in Combination with Immune Therapy Pembrolizumab as First-Line Treatment for Advanced Bladder CancerSeptember 28th, 2019
Professional Memberships
- Member
- Member
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
